BGNE BeiGene Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: BGNE

Price (delayed)

$177.99

Market cap

$18.38B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.55

Enterprise value

$14.71B

Highlights
BeiGene's quick ratio has increased by 6% YoY and by 5% QoQ
The equity has grown by 47% YoY but it has contracted by 6% from the previous quarter
BeiGene's debt has increased by 5% YoY but it has decreased by 3.3% from the previous quarter
The net income has dropped by 64% year-on-year and by 35% since the previous quarter
The company's EPS fell by 49% YoY and by 32% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.beigene.com/
Peers: OCUP

Key stats

What are the main financial stats of BGNE
Market
Shares outstanding
103.28M
Market cap
$18.38B
Enterprise value
$14.71B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.11
Price to sales (P/S)
20.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.77
Earnings
Revenue
$877.04M
EBIT
-$1.92B
EBITDA
-$1.87B
Free cash flow
-$1.93B
Per share
EPS
-$1.55
Free cash flow per share
-$18.78
Book value per share
$57.26
Revenue per share
$8.55
TBVPS
$77.76
Balance sheet
Total assets
$8.02B
Total liabilities
$2.14B
Debt
$671.88M
Equity
$5.89B
Working capital
$5.57B
Liquidity
Debt to equity
0.11
Current ratio
5.05
Quick ratio
4.68
Net debt/EBITDA
1.97
Margins
EBITDA margin
-212.8%
Gross margin
77.5%
Net margin
-218.2%
Operating margin
-222.6%
Efficiency
Return on assets
-27.9%
Return on equity
-40.1%
Return on invested capital
-60.5%
Return on capital employed
-28.9%
Return on sales
-218.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BGNE stock price

How has the BeiGene stock price performed over time
Intraday
13.95%
1 week
34.7%
1 month
44.72%
1 year
-49.48%
YTD
-34.3%
QTD
-5.63%

Financial performance

How have BeiGene's revenue and profit performed over time
Revenue
$877.04M
Gross profit
$679.58M
Operating income
-$1.95B
Net income
-$1.91B
Gross margin
77.5%
Net margin
-218.2%
BGNE's operating margin has dropped by 82% since the previous quarter and by 58% year-on-year
BeiGene's net margin has plunged by 82% from the previous quarter and by 61% YoY
The net income has dropped by 64% year-on-year and by 35% since the previous quarter
BeiGene's operating income has shrunk by 61% YoY and by 36% QoQ

Growth

What is BeiGene's growth rate over time

Valuation

What is BeiGene stock price valuation
P/E
N/A
P/B
3.11
P/S
20.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.77
The company's EPS fell by 49% YoY and by 32% QoQ
The price to book (P/B) is 53% lower than the last 4 quarters average of 6.6 and 50% lower than the 5-year quarterly average of 6.2
The equity has grown by 47% YoY but it has contracted by 6% from the previous quarter
BGNE's price to sales (P/S) is 42% lower than its 5-year quarterly average of 36.1 and 23% lower than its last 4 quarters average of 27.1
The revenue has contracted by 25% from the previous quarter

Efficiency

How efficient is BeiGene business performance
The company's return on sales has shrunk by 81% QoQ and by 60% YoY
BeiGene's ROIC has plunged by 69% YoY and by 40% from the previous quarter
BGNE's return on equity is down by 26% year-on-year and by 22% since the previous quarter
The company's return on assets fell by 25% YoY and by 25% QoQ

Dividends

What is BGNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BGNE.

Financial health

How did BeiGene financials performed over time
The total assets has increased by 38% year-on-year but it has declined by 7% since the previous quarter
BGNE's total liabilities is up by 18% year-on-year but it is down by 11% since the previous quarter
BeiGene's debt is 89% less than its equity
The equity has grown by 47% YoY but it has contracted by 6% from the previous quarter
BeiGene's debt to equity has decreased by 31% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.